Yale University

Expanded screening for HIV in the United States--an analysis of cost-effectiveness.

TitleExpanded screening for HIV in the United States--an analysis of cost-effectiveness.
Publication TypeJournal Article
Year of Publication2005
AuthorsPaltiel, David A., Milton C. Weinstein, April D. Kimmel, George R. Seage, Elena Losina, Hong Zhang, Kenneth A. Freedberg, and Rochelle P. Walensky
JournalThe New England journal of medicine
Volume352
Issue6
Pagination586-95
Date Published2005 Feb 10
ISSN1533-4406
KeywordsAnti-Retroviral Agents, Antiretroviral Therapy, Highly Active, Computer Simulation, Cost-Benefit Analysis, Disease Progression, Enzyme-Linked Immunosorbent Assay, Health Care Costs, HIV Antibodies, HIV Infections, Humans, Mass Screening, Monte Carlo Method, Quality-Adjusted Life Years, Risk Factors, United States
AbstractAlthough the Centers for Disease Control and Prevention (CDC) recommend routine HIV counseling, testing, and referral (HIVCTR) in settings with at least a 1 percent prevalence of HIV, roughly 280,000 Americans are unaware of their human immunodeficiency virus (HIV) infection. The effect of expanded screening for HIV is unknown in the era of effective antiretroviral therapy.
DOI10.1111/j.1524-4733.2010.00763.x
Alternate JournalN. Engl. J. Med.

External Links